PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial
View HTML
Toggle Summary Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
Patent supports the Combination Immunotherapy trial utilizing GR-MD-02, now completed enrollment of second ascending dose cohort
View HTML
Toggle Summary Galectin Therapeutics to Present at the Singular Research Summer Conference
NORCROSS, Ga. , July 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin , Ph.D., the Company's chief operating officer, will be presenting on behalf of the Company at the
View HTML
Toggle Summary Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
NORCROSS, Ga., June 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Galacto-Rhamnogalacturonate compositions for the treatment of a number of diseases associated with...
View HTML
Toggle Summary Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS
View HTML
Toggle Summary Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer, announces the independent data safety monitoring board (DSMB) recently concluded that, from a safety perspective, the Company's NASH-CX trial sh...
View HTML
Toggle Summary Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial
View HTML
Toggle Summary Autoimmune Disease Patent Granted to Galectin Therapeutics
NORCROSS, Ga., June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has been issued U.S. Patent 9,649,327 for "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." The patent's principal claims cover me...
View HTML
Toggle Summary Autoimmune Disease Patent Granted to Galectin Therapeutics
NORCROSS, Ga. , June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has been issued U.S. Patent 9,649,327 for "Composition of Novel Carbohydrate Drug for Treatment of
View HTML
Toggle Summary Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update View HTML